Aflibercept 8 mg and eylea® (aflibercept) injection presentations at arvo provide new insights into the treatment of serious retinal diseases

New subgroup data and further analyses of the aflibercept 8 mg clinical trial program to highlight durability results of extended dosing intervals, patient characteristics, and efficacy and safety in wet age-related macular degeneration and diabetic macular edema
REGN Ratings Summary
REGN Quant Ranking